KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Accuray (ARAY) Other financing activities (2022 - 2026)

Accuray posted quarterly Other financing activities of $3000.0 for Q1 2026, down 98.27% year-on-year from $173000.0 in Q1 2025, and down 93.75% on a QoQ basis from $48000.0 in Q4 2025.

Accuray (ARAY) has 5 years of Other financing activities data on file, last reported at $3000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other financing activities fell 98.27% year-over-year to $3000.0; the trailing twelve-month figure through Mar 2026 stood at $224000.0 (down 48.62% YoY), and the FY2025 full-year result was $90000.0, up 11.11% from the prior year.
  • Other financing activities for Q1 2026 stood at $3000.0, down from $48000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $248000.0 in Q1 2023 and bottomed at $3000.0 in Q1 2026.
  • The 5-year median for Other financing activities is $116500.0 (2022), against an average of $121000.0.
  • The widest annual swing landed in 2023, when Other financing activities rose 0.86%; it then slumped 98.27% in 2026.
  • A 5-year view of Other financing activities shows it stood at $116000.0 in 2022, then increased by 0.86% to $117000.0 in 2023, then decreased by 23.08% to $90000.0 in 2024, then slumped by 46.67% to $48000.0 in 2025, then tumbled by 93.75% to $3000.0 in 2026.
  • The last three Other financing activities figures came in at $3000.0 (Q1 2026), $48000.0 (Q4 2025), and $173000.0 (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Accuray 47,295.88 -38.49 Mn 25.29 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 3,000.00
Mar 31, 2026 3,000.00
Dec 31, 2025 48,000.00
Dec 31, 2025 48,000.00
Mar 31, 2025 173,000.00
Mar 31, 2025 173,000.00
Dec 31, 2024 90,000.00
Dec 31, 2024 90,000.00
Sep 30, 2024 173,000.00
Sep 30, 2024 173,000.00
Dec 31, 2023 117,000.00
Dec 31, 2023 117,000.00
Mar 31, 2023 248,000.00
Mar 31, 2023 248,000.00
Dec 31, 2022 116,000.00
Dec 31, 2022 116,000.00